Non-Steroidal Anti-Inflammatory Drug (NSAID) Response and Central Sensitization of Pain in Women With Dysmenorrhea
Dysmenorrhea, Menstrual Pain, Non-steroidal Anti-inflammatory Drug
About this trial
This is an interventional other trial for Dysmenorrhea
Eligibility Criteria
Inclusion Criteria: Female aged 18-50 years Menstrual pain rated at least 6/10 on a 0 (no pain) to 10 (worst pain possible) NRS for all menstrual cycles in the previous 6 months Regular menstrual cycles over the past year (at least 9 in the previous 12 months) Self-reported menstrual cycle averaging 22-35 days Access to a smartphone and email, and willing/able to receive text messages Able to read and understand English Ability and willingness to provide written informed consent. Exclusion Criteria: Use of oral contraceptives or any exogenous hormones in the previous 3 months prior to participation Variable levels of menstrual pain in the previous 6 months Self-reported symptoms consistent with a chronic pain condition (e.g., pain in any body area lasting longer than 3 months) or previous diagnosis of a chronic pain condition Currently pregnant or breastfeeding History of pelvic inflammatory disease or sexually transmitted disease Acute illness or injury that would potentially impact pain task performance (e.g., fever, flu symptoms) or that affect sensitivity of the extremities (e.g., Reynaud's disease) Allergy to naproxen or having a health condition that contradicts use of naproxen or affects naproxen metabolism (e.g., kidney disease) History of high blood pressure or anemia (due to possible complications from NSAID use).
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Sodium Naproxen first
Placebo first
Participants take the dose of sodium naproxen during the first menstrual cycle and take the placebo during the second menstrual cycle.
Participants take the dose of placebo during the first menstrual cycle and take the sodium naproxen during the second menstrual cycle.